Sanofi: UBS reiterates buy recommendation
(CercleFinance.com) - Sanofi has reported business EPS of E2.
86 for Q3 2024, up 12.2% as reported and 17.6% at constant exchange rates (CER), on sales of over $13.4bn, up 12.3% (+15.7% CER).
Following this publication, UBS confirms its Buy recommendation on the share, with an unchanged target price of E110.
Sales were solid in the third quarter, with early recognition of the profitability gains expected for fiscal 2025. Growth diversification away from Dupixent supports revaluation potential, it says.
Note that Sanofi has raised its outlook for 2024, now expecting business EPS growth at CER at least in the low single-digit range, supported by strong business performance.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.
86 for Q3 2024, up 12.2% as reported and 17.6% at constant exchange rates (CER), on sales of over $13.4bn, up 12.3% (+15.7% CER).
Following this publication, UBS confirms its Buy recommendation on the share, with an unchanged target price of E110.
Sales were solid in the third quarter, with early recognition of the profitability gains expected for fiscal 2025. Growth diversification away from Dupixent supports revaluation potential, it says.
Note that Sanofi has raised its outlook for 2024, now expecting business EPS growth at CER at least in the low single-digit range, supported by strong business performance.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.